Second Stelara Biosimilar Selarsdi Gets FDA Approval

By Maaisha Osman / April 18, 2024 at 6:10 PM
FDA has approved a second biosimilar version of the widely used injection psoriasis drug Stelara, which will be known as Selarsdi. It’s slated to enter the market on or after Feb. 21, 2025, following a settlement with Johnson & Johnson, the manufacturer of Stelara. If Stelara’s biosimilars capture a large enough market share, they could impact the drug’s status as one of the 10 drugs initially selected for CMS’ inaugural drug price negotiation program. The biosimilar makers Alvotech and Teva...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.